Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
180 Life Sciences Corp. Common Stock (symbol: ATNF) represents a pioneering clinical-stage biotechnology company based in Menlo Park, California. The company focuses on developing innovative therapeutics to address unmet medical needs in chronic pain, inflammation, and fibrosis.
The company has several key product development platforms currently in Phase IIb/III clinical trials:
- Fibrosis and Anti-TNF Platform: This platform targets the treatment of fibrosis and anti-tumor necrosis factors, a major cause of inflammation.
- Synthetic Cannabidiol (CBD) Analogs Platform: This platform includes man-made derivatives of CBD designed to offer therapeutic benefits.
- α7nAChR Platform: Focused on the alpha 7 nicotinic acetylcholine receptor, which plays a role in modulating inflammation and pain.
180 Life Sciences Corp. is committed to advancing its drug candidates through robust clinical trials and cutting-edge research. From addressing postoperative pain relief with orally absorbed CBD tablets to combating chronic inflammation and fibrosis, the company's innovative approach highlights its significance in the biotechnology landscape.
The company’s recent achievements include a notable presentation by Dr. Michael J. Alaia at the 2022 American Academy of Orthopaedic Surgeons Annual Meeting. The talk focused on the efficacy of CBD tablets for postoperative pain relief, showcasing the potential impact of 180 Life Sciences Corp.'s therapies.
For more information, investors can contact Jason Assad, Director of Investor Relations, at jassad@180lifesciences.com.
180 Life Sciences Corp. (NASDAQ: ATNF) has completed a private placement of 2,500,000 shares and warrants, raising approximately $15 million. The shares were priced at $6.00 each, with warrants exercisable at $7.50. The net proceeds will support general corporate needs and R&D initiatives. Maxim Group LLC acted as the placement agent. These securities are unregistered and available only to accredited investors. The company is engaged in developing drugs for inflammatory diseases, leveraging expertise from prestigious universities.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a private placement to raise approximately $15.0 million through the sale of 2,500,000 shares of common stock and accompanying warrants. The combined purchase price is $6.00 per share and warrant, with warrants exercisable at $7.50 each for five years. The closing is anticipated on August 23, 2021, pending customary conditions. Maxim Group LLC is the placement agent. The offering is aimed at accredited investors and includes registration rights for resale of the shares.
180 Life Sciences Corp. (NASDAQ: ATNF) announced that Jagdeep Nanchahal, Professor of Hand Surgery, will present a keynote speech on September 9, 2021, at the British Society for Surgery of the Hand meeting. The presentation will cover his research on Dupuytren's disease and potential treatments targeting fibrotic processes. Dr. James Woody, CEO of 180 Life Sciences, expressed enthusiasm for sharing this significant scientific work with experienced clinicians.
180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology firm, announced that CEO Dr. James Woody and Professor Jagdeep Nanchahal will participate in the BTIG Virtual Biotechnology Conference from August 9-10, 2021. Their fireside chat is scheduled for August 10 at 1:00 PM ET. The conference will feature discussions on the company's innovative drug development targeting inflammatory diseases and fibrosis. A replay will be available for BTIG clients after the event. 180 Life Sciences is focused on addressing significant unmet medical needs in inflammation and pain.
180 Life Sciences Corp. (NASDAQ: ATNF) has selected a lead synthetic CBD analogue for clinical development targeting inflammation and pain. Collaborating with cannabis chemistry pioneer Professor Raphi Mechoulam and Sir Marc Feldmann, the company identified this non-psychoactive compound from numerous CBD derivatives. The analogue shows potential patent protection, strong preclinical efficacy, and scalability for GMP manufacturing. CEO Dr. James Woody expressed optimism for HUM-217's advancement in clinical trials, marking a significant progress in cannabinoid use in medicine.
180 Life Sciences Corp. (NASDAQ: ATNF) has regained compliance with Nasdaq's listing rule 5250(c)(1) after timely filing its annual and quarterly reports. After previous non-compliance notifications due to late filings of the 2020 Form 10-K and Q1 2021 Form 10-Q, the company submitted these documents on July 9 and July 19, 2021, respectively. Nasdaq confirmed compliance on July 19, 2021, indicating the matter is closed. 180 Life Sciences focuses on developing novel drugs targeting inflammatory diseases, leveraging expertise from top universities.
180 Life Sciences Corp. (NASDAQ: ATNF) announced on July 12, 2021, that it regained compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2) after appointing new independent directors, thereby closing a compliance matter. The company had previously been notified of non-compliance by Nasdaq, which provided a 45-day period to submit a plan. After timely submission and an extension, the appointment of Pamela G. Marrone and Francis Knuettel II allowed the company to meet all requirements for continued listing.
180 Life Sciences Corp. (NASDAQ: ATNF) announced the publication of a review titled “Collagen VI as a driver and disease biomarker in human fibrosis” in the FEBS Journal. The study, authored by researchers from the University of Oxford, highlights the role of microfibrillar collagen VI in fibrotic diseases affecting vital organs. It identifies collagen VI cleavage fragments as potential biomarkers and therapeutic targets for fibrotic conditions. This publication underscores the company's commitment to advancing drug development for inflammatory diseases and fibrosis.
180 Life Sciences Corp. (NASDAQ: ATNF) announced its inclusion in the Russell Microcap® Index, effective June 28, 2021. This membership is expected to enhance the company’s visibility, increase stock liquidity, and broaden its shareholder base as the Russell indexes are widely used benchmarks for investment strategies.
CEO Dr. James Woody highlighted this inclusion as a pivotal validation for the company, aiming to propel long-term shareholder value. The Russell indexes are benchmarked by approximately $10.6 trillion in assets, indicating significant market relevance.
180 Life Sciences Corp. (ATNF) has been granted an extension until July 31, 2021, by Nasdaq to regain compliance with its listing rules after failing to file its 2020 Form 10-K and Q1 2021 Form 10-Q. The company initially received a notification regarding non-compliance on April 16, 2021, and submitted a compliance plan to Nasdaq by the June 15 deadline. The company is currently working to complete and file the overdue reports to maintain its listing on the Nasdaq.
FAQ
What is the current stock price of 180 Life Sciences (ATNF)?
What is the market cap of 180 Life Sciences (ATNF)?
What does 180 Life Sciences Corp. specialize in?
Where is 180 Life Sciences Corp. headquartered?
What are the key platforms of 180 Life Sciences Corp.?
What stage are the company's product development platforms in?
Who can be contacted for investor relations?
What is the focus of the recent talk presented by Dr. Michael J. Alaia?
What is the company's ticker symbol?
What unmet medical needs does 180 Life Sciences Corp. aim to address?
What is the significance of the α7nAChR platform?
How can I stay updated with the latest news about 180 Life Sciences Corp.?
